Clinical Trial

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 21, 2023 (before its estimated February 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Phase II Study to Assess the Efficacy and Safety of Cadonilimab Combined With Fruquintinib and SBRT as A third-line and Posterior Line Treatment in Patients With MSS Colorectal Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-05.
Trial Details
NCT Number NCT06168786
Lead Sponsor Huazhong University of Science and Technology
Conditions Colorectal Cancer
Enrollment 40 participants
Start Date 2023-06-20
Primary Completion 2026-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2023-12-21